NCT03269669 2026-03-18Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular LymphomaNational Cancer Institute (NCI)Phase 2 Active not recruiting73 enrolled